Results 81 to 90 of about 9,856 (174)

Abstracts From AIDS 2026, the 26th International AIDS Conference, 26 – 31 July 2026 Rio de Janeiro, Brazil & virtual

Journal of the International AIDS Society, Volume 29, Issue S4, July 2026.
wiley   +1 more source

分娩发动前后体内NK细胞、NKT细胞表型分析

Zhongguo shiyan zhenduanxue, 2009
目的研究分娩发动前后蜕膜及外周血中NK细胞、NKT细胞表面NKG2A和NKG2D受体的表达情况,探讨其在产程发动中的作用。方法选取正常孕足月孕妇分为分娩发动经阴道分娩组（以下简称分娩组20例）和分娩未发动行选择性剖宫产术组（以下简称剖宫产组20例）,分离蜕膜及外周血中单个核细胞后采用流式细胞学技术分别检测CD56+细胞、NK细胞、NKT细胞表面NKG2A和NKG2D受体的表达情况。结果外周血单个核细胞中分娩组CD56+NKG2A+细胞构成下降、CD56+NKG2D+细胞构成增加,NK细胞 ...
陈红波, 凌斌, 周颖, 冯定庆, 徐静竹, 黄大雁   +5 more
doaj  

Hantaan virus-derived peptides that stabilize HLA-E could abrogate inhibition of CD56dimNKG2A+ NK cells.

PLoS Pathogens
NK cells could participate in the pathogenesis process of virus infectious diseases through the inhibitory receptor CD94/NKG2A interacting with HLA-E/virus-derived peptide complex.
Manling Xue, Kang Tang, Yusi Zhang, Xiaoyue Xu, Chunmei Zhang, Jiajia Zuo, Fenglan Wang, Xiyue Zhang, Xuyang Zheng, Ran Zhuang, Yun Zhang, Boquan Jin, Ying Ma   +12 more
doaj   +1 more source

CRISPR/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells

Nature Communications
Chimeric antigen receptor (CAR)-modified natural killer (NK) cells show antileukemic activity against acute myeloid leukemia (AML) in vivo. However, NK cell-mediated tumor killing is often impaired by the interaction between human leukocyte antigen (HLA)-
Tobias Bexte, Nawid Albinger, Ahmad Al Ajami, Philipp Wendel, Leon Buchinger, Alec Gessner, Jamal Alzubi, Vinzenz Särchen, Meike Vogler, Hadeer Mohamed Rasheed, Beate Anahita Jung, Sebastian Wolf, Raj Bhayadia, Thomas Oellerich, Jan-Henning Klusmann, Olaf Penack, Nina Möker, Toni Cathomen, Michael A. Rieger, Katharina Imkeller, Evelyn Ullrich   +20 more
doaj   +1 more source

HLA-E single-chain trimer shields gene-edited allogeneic CAR T cells from NK cell attack. [PDF]

Blood Adv
Apodaca KM, Xu C, Stanton KL, Baroja ML, Alfaro Doblado AR, Engel NW, Wellhausen N, Cox A, Berjis A, Ji M, Bushara O, Perez DM, Welch C, Banerjee E, Assenmacher CA, Sheppard NC, Scholler J, June CH, Carreno BM, Linette GP.   +19 more
europepmc   +1 more source

Integrated Single-Cell Transcriptomics Identifies γδ T-Cell Heterogeneity and a Candidate HLA-E-NKG2A Regulatory Axis in Pancreatic Ductal Adenocarcinoma. [PDF]

Cancers (Basel)
Mandal S, Hasan SR, Dhali A, Maji M.
europepmc   +1 more source

Phase 1 multicenter study of the NKG2A targeting antibody S095029 as a single agent and in combination with anti-PD-1 in patients with advanced malignancies. [PDF]

J Immunother Cancer
Naing A, Spreafico A, Barve M, Patnaik A, Ianopoulos X, Drean P, Skartved NJ, Hemon A, Kantari-Mimoun C, He P, Askoxylakis V, Lakhani N.   +11 more
europepmc   +1 more source

NKG2A inhibition promotes NK cell-CD8⁺ T cell interactions to improve anticancer immunity in ovarian carcinoma. [PDF]

Nat Commun
Lanickova T, Angelidou A, Hensler M, Vankerckhoven A, Niederlova V, Vosahlikova S, Kasikova L, Bock A, Zacharova E, Stekas C, Tunkova B, Tomankova J, Glatzova D, Moserova I, Drozenova J, Cveckova B, Shankar T, Laco J, Ryska A, Dundr P, Ndukwe MI, Cibula D, Vachtenheim J, Lischke R, Capkova L, Kovar M, Halaska MJ, Rob L, Allonsius L, Laoui D, Hanns A, Cremer I, Orsulic S, Stepanek O, Jacob F, Galluzzi L, Spisek R, Fucikova J.   +37 more
europepmc   +1 more source

Designing universal T cell therapies: strategies to evade natural killer cells. [PDF]

Front Immunol
Bushara O, Linette GP, Carreno BM.
europepmc   +1 more source

Coevolution of NK and Tumor Cell States Along Multiple Myeloma Progression from Precursor Conditions. [PDF]

Int J Mol Sci
Aquilina C, Romano A, Corsale AM, Biondo M, Speciale M, Tofacchi E, Di Simone M, Gigliotta E, Dieli C, Avellone C, Toscano A, Camarda L, Romano A, Cambria D, Giavaresi G, Raimondi L, Neri A, Campana S, Caccamo N, Dieli F, Siragusa S, Meraviglia S, Botta C.   +22 more
europepmc   +1 more source